Ernie, right on target. If a stock goes up significantly before any pivotal data release, like EXEL has done, a good management team will issue some new shares to raise money as a form of insurance.
quorthon is a perfect example of a person who has nothing to say, but feels the need to keep saying it.
symonfund, just how many times are you going to post this virtually useless comment? There is no comparison between Entereg and Relistor. Entereg was used in healthy patients. Relistor was used in AMI patients, which stand for advanced medical illness. These are patients with advanced cancer and are taking opiates for pain, likely far more frequently and at higher doses than the healthy patients did. We would need to know the number of patients treated, when the low number of events occurred relative to drug treatment.
Obviously we don't know what the FDA will rule. There is a far different outcome for PGNX if they give approval in Chronic pain with a mandated phase IV follow-up vs a rejection due too need for a safely study.
It was 29 patients and 2 heart attacks over a 15 year period in AMI patients (advanced cancer patients) who were very sick and on thier last legs. Oh and those number are meaningless without how many patients were treated.
Stupid auto-correct. "but the near term could be quite choppy so lots of CHANCES to slowly book some profit and keep a decent core position"
chiraag, thankfully for patients, the prostate cancer market is becoming crowded. As far as the PGNX anti-PSMA-ADC, it is for patients who have been heavily treated and have failed other therapies, so there is still a need and therefore, a niche for PGNX.
Yes the SNTA board has become populated by fools, pumpers and bashers. My opinion of SNTA has been up and down. The concept of HSP90 inhibition as an anti-oncgenic agent is great, but the data has been mixed. Part of the reason is that management hasn't exactly been stellar in trial choices, and in data presentation and protections, but they do seem to have toned it down a bit now. I am shifting my mindset to sell some percentage of my holdings on price rises, then buy some back when, or if, the price drops rather than my more usual buy some then buy more when opportunities arise. The primary driver now is the NSCLC trials. The final data for the Galaxy-1 phase II trial should be out this quarter. SNTA has been placing that the data was distorted because a few Eastern European centers used first line patients, so the placebo arm had higher OS. Even if on accept this, you should note that they increased the size of the currently running phase III Galaxy-2 trial. The more positive signs are that SNTA is expanding trials into breast cancer, and now a European run and funded Ovarian cancer trial involving metastatic p53 mutant tumors. Major clients of HSP90 include ERBs (estrogen receptor binding proteins), so one might imagine the best chances for success are in breast and ovarian tumors. In the Galaxy-1 trial, if you look at the difference in sexes, women fared better than men. There are also three new European funded trials in leukemia (AML and MDS), so SNTA has a number of irons in the fire. Long-temr chances for success have been increased, but the near term could be quite choppy so lots of cancer to slowly book some profit and keep a decent core position.
striperman, the imaging agent work well but I haven't paid it much attention because PGNX got it for a song. Maybe I am mistaken for that view as even a small revenue producer means something to PGNX given its small market cap. I have been more concerned with the SLXP attempts to get the FDA to reverse its decision on the Relistor label expansion into the chronic pain indication.
ca_fisherman, I sold most of my shares off last year to book a tax loss to reduce what I owe on my ONXX profits. I meant to buy back some PGNX at the beginning of the year, but the price kept going up as I waited. I finally decided that I would at least stick my toes back in the water. The key event is still the FDA meeting of Relistor in chronic pain, although it is possible that the anti-PMSA antibody data will give us another boost so I acted now as a bit of insurance.
Don't be an idiot. Fast Track Status is given for unmet need, and isn't an indication of success.
Hey dung_king, I see you are still a nasty little cur making big claims about shorting a stock and attacking others who disagree. I remember when you claimed to have shorted MNTA at $10.50 and $11 last summer. You kept bragging about who smart you were and attacked those of us who owned MNTA and considered it a good investment. Well, MNTA is approaching $19 a share now. Great call numb nuts.
Relistor is already approved by the FDA and has been in the market for 3 or 4 years. PGNX is looking to get a label expansion.
On target once again Syenfout. Breast cancer is the most promising area for Ganetespib, but it is very early stage. We need to see some data for higher numbers of patients with Ganetespib as monotherapy, and perhaps more importantly, in combination with Paclitaxel. Management makes me angry with their incompetence. The Galaxy-1 and 2 Lung cancer trials are still viable, but the chances for success have been reduced. In any event. we will know more about Galaxy-1 in a few months when the final data comes in. Funny how that pumper Ivan has disappeared.